The trials of the BRAF/MEK inhibitors were limited to patients with BRAFV600E and BRAFV600K mutations and who showed an ORR between 60 and70%, which indicated that 30–40% of BRAF mutant melanoma patients did not respond to the targeted therapy. Here, MAP2K7 is linked to melanoma.